He Yujia, Johnston Angus P R, Pouton Colin W
Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Trends Biotechnol. 2025 Jan;43(1):83-97. doi: 10.1016/j.tibtech.2024.07.012. Epub 2024 Aug 16.
Engineering and reprogramming cells has significant therapeutic potential to treat a wide range of diseases, by replacing missing or defective proteins, to provide transcription factors (TFs) to reprogram cell phenotypes, or to provide enzymes such as RNA-guided Cas9 derivatives for CRISPR-based cell engineering. While viral vector-mediated gene transfer has played an important role in this field, the use of mRNA avoids safety concerns associated with the integration of DNA into the host cell genome, making mRNA particularly attractive for in vivo applications. Widespread application of mRNA for cell engineering is limited by its instability in the biological environment and challenges involved in the delivery of mRNA to its target site. In this review, we examine challenges that must be overcome to develop effective therapeutics.
通过替代缺失或有缺陷的蛋白质、提供转录因子(TFs)以重编程细胞表型,或提供诸如用于基于CRISPR的细胞工程的RNA引导的Cas9衍生物等酶,对细胞进行工程改造和重编程具有治疗多种疾病的巨大潜力。虽然病毒载体介导的基因转移在该领域发挥了重要作用,但使用mRNA可避免与DNA整合到宿主细胞基因组相关的安全问题,这使得mRNA在体内应用中特别具有吸引力。mRNA在细胞工程中的广泛应用受到其在生物环境中的不稳定性以及将mRNA递送至其靶位点所涉及的挑战的限制。在本综述中,我们探讨了开发有效治疗方法必须克服的挑战。